Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Oct 1;171(10):992-998.
doi: 10.1001/jamapediatrics.2017.1965.

Evaluation of Combination Measles-Mumps-Rubella-Varicella Vaccine Introduction in Australia

Kristine Macartney  1   2   3 , Heather F Gidding  1   4 , Lieu Trinh  5 , Han Wang  1 , Aditi Dey  1   2 , Brynley Hull  1 , Karen Orr  1   3 , Jocelynne McRae  1   3 , Peter Richmond  6   7 , Michael Gold  8   9 , Nigel Crawford  10   11 , Jennifer A Kynaston  12 , Peter McIntyre  1   2   3 , Nicholas Wood  1   2   3 ; Paediatric Active Enhanced Disease Surveillance Network
Affiliations

Evaluation of Combination Measles-Mumps-Rubella-Varicella Vaccine Introduction in Australia

Kristine Macartney et al. JAMA Pediatr. .

Abstract

Importance: Incorporating combination vaccines, such as the measles-mumps-rubella-varicella (MMRV) vaccine, into immunization schedules should be evaluated from a benefit-risk perspective. Use of MMRV vaccine poses challenges due to a recognized increased risk of febrile seizures (FSs) when used as the first dose in the second year of life. Conversely, completion by age 2 years of measles, mumps, rubella, and varicella immunization may offer improved disease control.

Objective: To evaluate the effect on safety and coverage of earlier (age 18 months) scheduling of MMRV vaccine as the second dose of measles-containing vaccine (MCV) in Australia.

Design, setting, and participants: Prospective active sentinel safety surveillance comparing the relative incidence (RI) of FSs in toddlers given MMRV and measles-mumps-rubella (MMR) and a national cohort study of vaccine coverage rates and timeliness before and after MMRV vaccine introduction were conducted. All Australian children aged 11 to 72 months were included in the coverage analysis, and 1471 Australian children aged 11 to 59 months were included in the FS analysis, with a focus on those aged 11 to 23 months.

Main outcomes and measures: MMRV vaccine safety, specifically, the RI of FSs after MMRV vaccine at age 18 months, compared with risk following MMR vaccine and vaccine uptake for 2-dose MCV and single-dose varicella vaccine, focusing on timeliness.

Results: Of the 1471 children, the median age at first FS was 21 months (interquartile range [IQR], 14-31 months). Three hundred ninety-one children were aged 11 to 23 months and had at least 1 FS included in the analysis; of these, 207 (52.9%) were male. A total of 278 children (71.1%) had received MMR followed by MMRV vaccine, 97 (24.8%) had received MMR vaccine only, and 16 (4.1%) had received neither vaccine. There was no increased risk of FSs (RI, 1.08; 95% CI, 0.55-2.13) in the 5 to 12 days following MMRV vaccine given as the second MCV to toddlers. Febrile seizures occurred after dose 1 of MMR vaccine at a known low increased risk (RI, 2.71; 95% CI, 1.71- 4.29). Following program implementation, 2-dose MCV coverage at age 36 months exceeded that obtained at age 60 months in historical cohorts recommended to receive MMR vaccine before school entry, and on-time vaccination increased by 13.5% (from 58.9% to 72.4%). Despite no change in the scheduled age of varicella vaccine, use of MMRV vaccine was associated with a 4.0% increase in 1-dose varicella vaccine coverage.

Conclusions and relevance: To our knowledge, this is the first study to provide evidence of the absence of an association between use of MMRV vaccine as the second dose of MCV in toddlers and an increased risk of FSs. Incorporation of MMRV vaccine has facilitated improvements in vaccine coverage that will potentially improve disease control.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: None reported.

Figures

Figure.
Figure.. Proportion of Children With On-Time Vaccination for Dose 2 of Measles-Containing Vaccine Before and After Measles-Mumps-Rubella-Varicella (MMRV) Vaccine Introduction
On-time vaccination was defined as vaccine receipt within 30 days of the recommended age. MMR indicates measles-mumps-rubella; MMR2, dose 2 of MMR-containing vaccine in cohort born between July 1 and December 31, 2012 (A) and cohort born between January 1 and June 30, 2009 (B).
See this image and copyright information in PMC

Comment in

References

    1. Corben P, Leask J. To close the childhood immunization gap, we need a richer understanding of parents’ decision-making. Hum Vaccin Immunother. 2016;12(12):3168-3176. - PMC - PubMed
    1. Jarrett C, Wilson R, O’Leary M, Eckersberger E, Larson HJ; SAGE Working Group on Vaccine Hesitancy . Strategies for addressing vaccine hesitancy—a systematic review. Vaccine. 2015;33(34):4180-4190. - PubMed
    1. World Health Organization Immunization, vaccines, and biologicals: implementation research in immunization. http://www.who.int/immunization/research/implementation/en/. Accessed July 6, 2017.
    1. Knuf M, Habermehl P, Zepp F, et al. . Immunogenicity and safety of two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children. Pediatr Infect Dis J. 2006;25(1):12-18. - PubMed
    1. Shinefield H, Black S, Digilio L, et al. . Evaluation of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children. Pediatr Infect Dis J. 2005;24(8):665-669. - PubMed

Publication types

Substances